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Diabetes is a chronic, degenerative, and non-
communicable disease associated with a high        
prevalence of cardiovascular morbidity and mortality.1,2 
The most recent estimates of the International Diabetes 
Federation (IDF) indicate that 8.3% of adults i.e. 382 
million people have diabetes, and the number of people 
with the disease is set to rise beyond 592 million in less 
than 25 years.3 It is worrying that 175 million of cases 
currently unaware of their diagnosis and progressing 
towards complications. Moreover, with 80% of the total 
number affected living in low- and middle-income 
countries, where the epidemic is gathering pace at 
alarming rates.  
 
According to IDF, approximately one-fifth of all adults 
with type 2 diabetes mellitus (T2DM) in the world live 
in the South-East Asia Region.3 Current estimates    
indicate that 8.2% of the adult population, or 72.1    
million people, have diabetes, 65.1 million of whom 
live in India. IDF also forecasted that the number of 
people with T2DM in the region will increase to 123 
million by 2035, or 8.2% of the adult population. A fur-
ther 24.3 million people have impaired glucose toler-
ance (IGT) , and this will increase to 38.8 million by 
2035. The number of people with T2DM in India,   
Bangladesh and Sri Lanka make up 98.8% of the total 
for the region. A recent systematic review and meta-
analysis conducted by Jayawardena et al.4 on prevalence 
and trends of the diabetes epidemic in South Asia high-
lighted that urban populations had a higher prevalence 
of diabetes. Moreover, an increasing trend in prevalence 
of diabetes was observed in urban/rural India and rural 
Sri Lanka. A high epidemicity index was seen in Sri 
Lanka (52.8%), while for other countries, the epidemic-
ity index was comparatively low (rural India: 26.9%; 
urban India: 31.3% and urban Bangladesh: 33.1%). It 
was also found that family history, urban residency, age, 
higher BMI, sedentary lifestyle, hypertension and waist-
hip ratio were associated with increased risks of T2DM. 
 
A sharp increase in the prevalence of T2DM has been 
observed in the SEA Region, both in urban and rural 
areas, which is mostly associated with lifestyles, high-
fat diets and decreased exercise.6 T2DM is the leading 
cause of CVD, renal disease, blindness and amputa-
tion.1,3 Cardiovascular disease (CVD) is a major compli-
cation and the leading cause of early death among peo-
ple with T2DM.1 About 65% of people with T2DM die 
from heart disease and stroke. Adults with T2DM are    
2-4 times more likely to have heart diseases or suffer a 
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stroke than people without T2DM. High blood glucose 
in adults with T2DM increases the risk of heart attack, 
stroke, angina, and coronary artery disease. The        
clustering of vascular risk led to the view that CV risk 
appears early, prior to the development of T2DM.1,6-9   
Progressive nature of both T2DM and associated CV 
risk poses specific challenges at different stages of the 
life of an individual with T2DM.1  
 
The complications of diabetic vasculopathy are       
commonly grouped into microvascular and macrovascu-
lar complications.2 In diabetes, macrovascular          
complications are the commonest cause of morbidity 
and mortality and are responsible for a high incidence of 
vascular diseases.1 Macrovascular diseases are tradition-
ally thought of as due to underlying obstructive     
atherosclerotic diseases affecting major arteries.2 The 
following pathological changes of major blood vessels 
occur which lead to functional and structural abnormali-
ties in diabetic vessels include endothelial dysfunction, 
reduced vascular compliance and atherosclerosis.2    
Besides, advanced glycation end product formation  
interacts with specific receptors that lead to overexpres-
sion of a range of cytokines. Haemodynamic pathways 
are activated in diabetes and are possibly amplified by 
concomitant systemic hypertension. Apart from these, 
hyperglycaemia, non-enzymatic glycosylation, lipid 
modulation, alteration of vasculature and growth factors 
activation contribute to development of diabetic vascu-
lopathy. This review focuses on pathophysiology and 
pathogenesis of diabetes-associated macrovasculopathy. 
Studies also demonstrated that following patient groups 
develop early manifestations of preclinical macrovascu-
lopathy: newly diagnosed, never-treated individuals 
with T2DM/IGT and no traditional CV risk factors, and 
normoglycemic and normotensive offspring of parents 
with T2DM/IGT.6-9 The presence of diabetes in parents 
constitutes increased risk of earlier onset of disease and 
its CVD complications in their offspring.9 The studies 
on arterial stiffness in young people and offspring of 
diabetic parents are scarce, and limited study was      
reported in the literature on the offspring of patients 
with IGT.9 
 
The modalities of treatment of diabetes includes:      
lifestyle modification (appropriate diet and exercise 
programs) and pharmacological intervention. Effective 
management of following reduce CV risks in diabetic 
patients: blood glucose, hypertension, blood lipid and 
blood hypercoagulability.1  
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Increased obesity and decreased physical activity are 
strongly linked with an increased prevalence and       
incidence of T2DM.3 Obesity is a predictor of both 
coronary heart disease and T2DM.1 About 80%–90% of 
DM is attributable to excess weight. Limited studies 
conducted to assess the effect of intensive lifestyle inter-
vention on CV outcome in T2DM.1 Look AHEAD 
(Action for Health in Diabetes) study demonstrated that 
weight loss did not reduce the rate of CV events in over-
weight or obese adults with DM.10 
 
Prolonged hyperglycaemia is a major factor in the 
pathogenesis of diabetic vasculopathy.1,2 Observational 
studies11,12 found positive correlations between       
measures of glycaemic control and CV outcomes;    
however, clinical trials13-16 failed to show consistent 
beneficial effects on cardiovascular events. It was dem-
onstrated that glycaemic control reduces the risk of    
microvascular complications among patients with DM, 
but its effect on CVD is uncertain.17-19 Though the    
landmark UKPDS 3413 showed protective effect on 
CVD, CV mortality, and all-cause mortality in T2DM 
patients, the large randomized, controlled trials14,16,22 
found conflicting results.  
 
Patients with T2DM and blood pressure (BP) are always 
at increased risk of morbidity and mortality from CV 
events.1 Diabetic macrovasculopathy can be improved 
by lowering BP with antihypertensive drugs. Though a 
number of randomized controlled trials showed        
adequate aggressive BP control improves CV            
outcomes,20-21 but others16 found no positive results. 
 
Dyslipidemia also contributes substantially to CV    
complications in patients with T2DM.1 A number of 
studies have shown that lowering LDL cholesterol    
reduces the risk of major vascular events diabetic      
patients. Randomized controlled trials23 in T2DM have 
consistently shown that statins significantly reduce the 
risk of major primary and secondary CV endpoints but 
trials24-26 of fibrate therapy have shown mixed results. 
 
Atherosclerosis and vascular thrombosis are major    
contributors to diabetic vasculopathy.1 Platelets play a 
significant role in increasing the risk of CVD. Currently, 
aspirin is at the centre of this research and is widely 
recommended for primary prevention of CV events. 
Major guidelines27 recommended aspirin for primary 
prevention of CV events, however a number of trials28-30 
found that aspirin did not prevent a first cardiovascular 
event or death and recommended to continue aspirin for 
secondary prevention. However, other antiplatelet drugs 
(e.g. Clopidogrel) were also found to reduce the risk of 
CV events in DM patients.31.32   
 
There are a number of research gaps in the area of     
diabetes and macrovasculopathy which creates          
opportunities for the scientist/researchers to conduct 
clinical trials: (i) lifestyle: effect of exercise and diet on 
quality of life, morbidity, and mortality, with a special 
focus on CV outcomes, (ii) glycaemic control: effective 
pharmacological approaches for the management of 
hyperglycemia which also affect CVD risk reduction, 
(iii) blood pressure: aggressive BP control may be the 
most important factor in preventing adverse CV        
outcomes, (iv) lipid profiles: routine use of combination 
therapy with fibrate and statin to reduce CV risk as 
compared with statin alone, and (v) antiplatelet therapy: 
clear benefit of aspirin in the primary prevention of ma-
jor CV events in T2DM patients.  
 
Diabetes mellitus has reached epidemic proportions 
worldwide. South Asians are known to have an        
increased predisposition for diabetes which has become 
an important health concern in the region.5 It is evident 
that several modifiable and non-modifiable risk factors 
play an important role in the pathogenesis of diabetes 
among South Asians. Hence there is an urgent need for 
more research to develop preventive and curative    
strategies to prevent diabetic epidemic in the region. 
The relationship of various degrees of glucose          
intolerance and CVD required to be investigated by 
longitudinal studies in different ethnic groups. 
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